To recover your password please fill in your email address
Please fill in below form to create an account with us
IMPACT-ICO
A multi-centre trial of colchicine vs control to improve clinical outcomes in adults long-SARS-CoV-2 (COVID-19)
|
Trial Summary: |
The aim of this study is to evaluate the ability of low-dose anti-inflammatory colchicine treatment compared to standard of care, to reduce host injury to the lungs and heart and both short- and long-term adverse outcomes in those hospitalised with symptomatic COVID-19 (swab-positive PCR) related infections. |
|
Supported By: |
MRFF |
|
Eligibility: |
Patients with SARS CoV2 COVID-19, who are in hospital and require oxygen support. |
|
Registration ID: |
ACTRN12621000637842 (ANZCTR) |
|
Participation: |
Up to 1000 Australian participants |
|
Australian Lead Group: |
CTC |
|
Status: |
Recruiting |
|
Activation Date: |
December 2021 |
|
Chairs: |
|
|
Contact: |